Startup Rise EU News’ Post

Why people invested in Saleem Telemedicine WLL? 🌍💼🏥 It was a dark and uncertain time when my beloved family member fell gravely ill. Desperate to find the best possible care, we embarked on a global quest, scouring the corners of the earth for a doctor who could offer a glimmer of hope. Days turned into weeks, and our search seemed endless. But then, amidst the chaos, we discovered TellSaleem—a beacon of light in our darkest hour. With its revolutionary platform connecting patients with renowned medical experts worldwide, we finally found the expertise we desperately needed. Through tears of relief and gratitude, I realized the profound impact TellSaleem could have on countless families facing similar struggles. It wasn't just about investing in a platform; it was about investing in hope, in healing, and in the future of healthcare. That's why I made the decision to invest in TellSaleem—not just for financial gain, but to ensure that families like mine never have to endure the anguish of searching for the best care alone. Become an investor at TellSaleem and let's create a world where hope shines bright for all. Learn more: https://lnkd.in/eaxiF4HW Beban Crowdfunding #Beban #HopeFund #Venture #InvestInHope #InvestInHealth #TellSaleem #HealthcareRevolution 🌍💼🏥

More exciting investment news in #DigitalHealth: ✅ London based Mental Health triage & support start-up Limbic has closed a Series A round of $14M led by the Khosla Ventures. Amongst other things, the funds will be used to support Limbics US expansion efforts. Exciting times ahead for Ross Harper & the entire Limbic team. ✅ UK firm RYSE has closed a new $50M fund. The fund will focus on scaling cutting edge Digital Health & Health Technology ventures. We can expect to see advancements in Digital Diagnostics, Therapeutics, and Digital Medical Devices as a result of the new fund. Combatting a various hurdles faced by not only the NHS, but healthcare systems on a global scale. The first early stage venture to benefit from this fund has been announced as Braingaze. Led by Laszlo Bax & Hans Supèr, Braingaze is a Spanish digital detection and treatment health tech company that is developing apps to treat and support conditions including ADHD, ASD, and dyslexia in children. Links to both investors & start-ups in comments below. #funding #digitalhealth #investment

RxDiet Secures $3m Seed Funding to Improve Healthcare Outcomes Using AI-driven Food Plans A New York-based health tech company leveraging the power of AI to create medically formulated food plans, RxDiet, has raised $3 million in seed funding to address poor diet, the leading cause of many chronic conditions. Co-founded by Roman Kalista, MD, and Jan Škvařil, the company has received significant support in the seed round to expand its grocery network, strengthen its team, and extend services to diverse payers. The round was spearheaded by Giant Ventures, with contributions from other investors such as FORM Life and Better Ventures, alongside many angel investors including Immad Akhund from Mercury Bank. Read more: https://lnkd.in/gGx9Hg6R #fundingnews #FundingOpportunity #StartupFunding #StartupSuccess #HealthcareNews #HealthcareFunding #nextdigitalhealth #Wi4 #vineetagrawal

#meetthepanelist Less than a week left till our #ExecutivePanel "HealthTech Market. What to Expect in 2024?" and we are super excited to introduce our first panelist. Please meet Keren Kopilov, Partner and Head of Digital Health at Firstime VC, the chairwoman of JDRF ISRAEL –the Israeli association for Type 1 Diabetes, an affiliation of JDRF International, and an active board member at Medcase, BAIBYS™ Fertility, Serenus.AI and others.  Previously, Keren was the COO & CFO of Thetime Incubator and Firstime Group – building and working with companies from the seed stage. Prior to that, Keren was the COO , CFO, and commercial leader of IPG Reuveni Pridan. Keren brings over 20 years experience of in value creation in business, strategy, financials, operations, and investments. Keren holds MBA from Tel Aviv University, BA in Economics & Business from the Hebrew University of Jerusalem, and L.L.B. Keren will share her views on the outline for #healthtech #investments in 2024, explain what factors guide the investment decision, and what companies should do to maximize business continuity and investment potential in this period. We are excited to have Keren on the panel alongside Arik B., Gad Sakin, and Olga Rosenman and look forward to hearing her invaluable insights! Follow the link to reserve your spot: https://lnkd.in/dJBGkq_J #medtech #fundraising #businesscontinuity #digitalhealth #investor #investmenttrends

Now open: Become an investor in Levels with our Community Round! We’re excited to announce that we’re extending our Series A fundraise to let our supporters become investors in Levels. We’re hosting this Community Round on the platform Wefunder, which allows anyone—whether or not they’re an accredited investor—to make an investment. This is our second Community Round (the first raised $5m!), and our goal is to build a network of people who share our mission and values. Since our last raise, we’ve made significant progress: • Achieved 143% compounding annual revenue growth rate, 1,327% in total from 2020 to 2023. Revenue exceeded $21M in 2023 • Helped more than 60k customers improve their metabolic health • Collected 700M+ glucose data points (11,000 years of continuous data) and 7M+ food logs; shipped more than 500k CGMs • Maintained 2+ years of financial runway and $15.8M in cash on hand as of 12/31/2023 • Raised $46M to date, backed by leading VC firms, including a16z, Trust, and Shrug, plus our broad network of Community Round investors To make an investment, please go to wefunder.com/levels, read our updated pitch, and click the orange ‘Invest’ button on the right side of the page. #metabolichealth #metabolism #CGM #levelshealth #healthtips #healthy #healthylife #bloodsugar

It’s incredibly humbling to be part of such a significant category for care transformation, on a national scale. As our CMO Sameer Berry says, “In GI, it’s the patient that drives the utilization of care” – which shows up when they’re not feeling well and can’t get in to see a specialist, they turn to the emergency room. This is why GI symptoms are the #1 cause of avoidable ER visits. Without access to high-touch multidisciplinary care, it can take years to get to a diagnosis and the root cause of GI issues. Along the way patients are racking up costs and often spinning in circles. When patients have access to Oshi care – as much care as they need to feel better and ideally with no out of pocket costs and fixed costs for the employer/plan – they get to the answers they seek. They are empowered through longer visits, frequent touchpoints, conservative interventions (that patients appreciate) and true medical care that uses all of the evidence-based clinical levers to get them feeling better, faster, and able to keep their symptoms under control. It takes a powerful coalition of clinicians, leaders, partners and investors to truly make a difference in our healthcare system. There’s something special happening here. Thank you to Oak HC/FT and all of our amazing investors: Bessemer Venture Partners, Frist Cressey Ventures, Takeda Digital Ventures, Koch Disruptive Technologies, Flare Capital Partners and CVS Health Ventures for your continued commitment and support of this important mission. And none of this is possible without innovative employers and health plans partnering with us to ensure that this care is accessible and top of mind for their members. A wise friend often says “better is possible”, and this funding increases the likelyhood that millions of people with digestive diseases can realize that fact.

PA-based #NewSpring Secures over $180M for Fourth Growth Equity Healthcare Fund. With over 20 years of experience investing in companies that help various segments of the #healthcare ecosystem transform the way patients are cared for, #NewSpring Healthcare is a thesis-driven, domain-specific growth equity strategy. Both new and current investors, including a wide range of family offices, financial institutions, and #strategists, backed NSH IV. Using primary and secondary research, its team focuses on proprietary deal flow and finds industries that have an important effect on #healthcare. Prior to the final close, NSH IV has already made six investments: AeroSafe Global, a provider of specialised #pharmaceutical distribution services; BetterNight, an entire sleep disorders management solution; and #Cardiovascular Staffing Leader. In order to generate #quantifiable value for business owners and Limited Partners, NewSpring collaborates with lower-middle market companies. They strive for excellence, build strong, long-lasting #relationships, and match their objectives and principles with those of business owners, financiers, and staff members. NewSpring Greg Barger Jim Ashton Michael DiPiano To share your startup story write us on - contact@startuprise.io #newspring #funding #startup

#fundingalert 💼Company: PharmaCord 💰Funding: Undisclosed ⚡Round: New Round 👥Investors: Permira PharmaCord is a patient services company, trusted by top manufacturers to improve medication access, adherence, and patient satisfaction. With their help, patients have a better experience with their critical therapies. The money will be used by the company to #grow both its operations and its clientele. Along with the Permira funds, PharmaCord’s founder and CEO, Nitin Sahney, and the management group will continue to hold key positions and drive the organisation. Read more - https://lnkd.in/gmts7hMt To share your startup story write us on - contact@startuprise.io #PharmaCord #patientservicescompany #medication #funding #fundingnews #news #startup #startupnews #startuprise

#London-based Evaro secures $1.5Million in seed #funding. Cornerstone VC and Exceptional Ventures led the round, including participation from the University of East Anglia and Syndicate Room, Catalisi’s investing arm. With the money, the business will expand into the B2B #sector by developing a plug-and-play solution that would enable #consumer brands to give their clients managed #prescription services. With the funds, Evaro will be able to provide 2,000 #treatments instead of just 200, covering 70% of the minor health conditions that NHS doctors generally #treat. The organization also hopes to obtain a treatment #Quality Commission (CQC) license, which would allow for more thorough patient treatment, including the beginning of therapy and #diagnosis. With only one line of code, they allow brands to easily #incorporate prescription medicine services into their product offers. For forward-thinking companies wishing to get into the #digital health market, Evaro offers a turnkey solution. Evaro Cornerstone VC Exceptional Ventures SyndicateRoom Thuria Wenbar Oskar Wendowski PhD To share your startup story write us on - contact@startuprise.co.uk #evaro #funding #eustartup

Intron Health Raises $1.6M in Pre-seed Funding Led by Microtraction === Intron Health, a pioneering health tech company that provides clinical speech recognition for over 200 accents spoken in developing countries, starting in Africa, has raised $1.6M in a pre-seed funding round. The round was led by Microtraction, with participation from Plug and Play Ventures, Jaza Rift, Octopus Ventures, Africa Health Ventures, OpenseedVC, Pi Campus, Alumni Angel, and Baker Bridge Capital. The investment also saw contributions from angel investors from global companies, including Google, CLEAR Global, NYU, and Optum Ventures. Launched in 2020 to digitise healthcare, Tobi Olatunji MD, Intron founder, quickly recognised data entry was a massive bottleneck to electronic medical record adoption. === READ MORE: https://lnkd.in/d_Y9FsCi